| abstract |
The present invention relates to combination therapy with oncolytic viruses, particularly oncolytic adenoviruses, and checkpoint inhibitors for the treatment of cancer, particularly to a combination comprising (a) an oncolytic adenoviral vector encoding tumor necrosis factor alpha (TNFalpha) and/or interleukin-2 (IL-2) as a transgene and (b) one or more immune checkpoint inhibitors for use in the treatment of cancer. |